Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Rasburicase for Hyperuricemia
- Conditions
- Nutritional and Metabolic Diseases
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2009-03-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT00290992
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 42
- Registration Number
- NCT00291005
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide
- Conditions
- Lung CancerPulmonary NeoplasmsSmall Cell Lung Cancer
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2008-12-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 432
- Registration Number
- NCT00290953
- Locations
- 🇳🇱
Sanofi-aventis adminsitrative office, Gouda, Netherlands
🇬🇧Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2009-08-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 390
- Registration Number
- NCT00290927
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 1
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2009-08-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 250
- Registration Number
- NCT00290979
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Glulisine Pre- and Postmeal
- Conditions
- Diabetes Mellitus Type 1
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT00290043
ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH
- Conditions
- Prostatic HyperplasiaAcute Urinary Retention
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 800
- Registration Number
- NCT00290030
Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2009-04-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 368
- Registration Number
- NCT00288236
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
Telithromycin in Acute Exacerbation of Chronic Bronchitis
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2009-12-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 54
- Registration Number
- NCT00288223
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease
- Conditions
- Alzheimer Disease
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2008-12-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 390
- Registration Number
- NCT00285077
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden